Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHPS | P49366 | 15/20 | 0.80 |
| ▸ | EDNRA | P25101 | 5/20 | 0.67 |
| ▸ | EDNRB | P24530 | 4/20 | 0.67 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.58 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.58 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30412442 | 0.89 | DHPS (1.00) | DHPSEDNRAEDNRB | |
| SCHEMBL7700301 | 0.89 | DHPS (0.64) | DHPSEDNRAEDNRB | |
| SCHEMBL28573181 | 0.89 | DHPS (1.00) | DHPSEDNRAEDNRB | |
| SCHEMBL4066788 | 0.88 | DHPS (0.85) | DHPSEDNRAEDNRB | |
| SCHEMBL4060092 | 0.88 | EDNRB (0.67) | DHPSEDNRAEDNRB | |
| SCHEMBL15384645 | 0.88 | EDNRA (0.67) | DHPSEDNRAEDNRBABCC3ABCC4 | |
| SCHEMBL4061140 | 0.87 | EDNRA (0.67) | DHPSEDNRAEDNRBABCC3ABCC4 | |
| SCHEMBL1009078 | 0.87 | EDNRA (0.66) | DHPSEDNRAEDNRBABCC3ABCC4 | |
| SCHEMBL7209693 | 0.86 | DHPS (0.58) | DHPS | |
| SCHEMBL30411955 | 0.86 | DHPS (1.00) | DHPSEDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2550256-B1 | PROCESS FOR THE PREPARATION OF BOSENTAN | LESVI LABORATORIOS SL (ES) | 2015-07-15 | — | — | EP | disclosed |
| WO-2011117143-A1 | PROCESS FOR THE PREPARATION OF BOSENTAN | LABORATORIOS LESVI, S.L. (ES) | 2011-09-29 | — | — | WO | disclosed |
| EP-2368884-A1 | Process for the preparation of bosentan | Laboratorios Lesvi, S.L. (ES) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010012637-A1 | PROCESS FOR THE PREPARATION OF BOSENTAN | INKE, S.A. (ES) | 2010-02-04 | — | — | WO | disclosed |
| EP-1322624-B1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-21 | — | — | EP | disclosed |
| US-7323465-B2 | Alkansulfonamides as endothelin antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-01-29 | — | — | US | disclosed |
| US-7091201-B2 | Arylalkane-sulfonamides having endothelin-antagonist activity | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-15 | — | — | US | disclosed |
| US-20050085639-A1 | Novel alkansulfonamides as endothelin antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-04-21 | — | — | US | disclosed |
| EP-1465875-A1 | NOVEL ALKANSULFONAMIDES AS ENDOTHELIN ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2004-10-13 | — | — | EP | disclosed |
| US-20040102464-A1 | Arylalkane-sulfonamides having endothelin-antagonist activity | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-05-27 | — | — | US | disclosed |
| WO-2003055863-A1 | NOVEL ALKANSULFONAMIDES AS ENDOTHELIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2003-07-10 | — | — | WO | disclosed |
| EP-1322624-A1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | Actelion Pharmaceuticals Ltd. (CH) | 2003-07-02 | — | — | EP | disclosed |
| EP-0959072-B1 | Sulfonamide derivative and process for preparing the same | TANABE SEIYAKU CO (JP) | 2002-09-25 | — | — | EP | disclosed |
| WO-2002024665-A1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | ACTELION PHARMACEUTICALS LTD (CH) | 2002-03-28 | — | — | WO | disclosed |
| EP-0959072-A1 | Sulfonamide derivative and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1999-11-24 | — | — | EP | disclosed |
| US-5739333-A | 4-SULFONAMIDO-6-ARYLOXY OR -AMINOALKYLENEOXY,-AMINO, OR -THIOPYRIMIDINES; ENDOLTHELIN ANTAGONISTS; HYPOTENSIVE AND ULCER AGENTS; ASTHMA; RAYNAUD DISEASE; CARDIOVASCULAR DISORDERS | TANABE SEIYAKU CO., LTD. (JP) | 1998-04-14 | — | — | US | disclosed |
| EP-0743307-A1 | Sulfonamide derivative and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1996-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085639-A1 | Novel alkansulfonamides as endothelin antagonists | EDNRA, EDNRB, ECE1 | DHPS 2156/4885EDNRA 1/4885EDNRB 2/4885 |
| US-20040102464-A1 | Arylalkane-sulfonamides having endothelin-antagonist activity | EDNRA, EDNRB, ECE2 | DHPS 1235/4885EDNRA 1/4885EDNRB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.